Savara’s (SVRA) “Buy” Rating Reiterated at HC Wainwright

Savara (NASDAQ:SVRAGet Free Report)‘s stock had its “buy” rating restated by HC Wainwright in a report released on Monday, Benzinga reports. They presently have a $6.00 target price on the stock. HC Wainwright’s price objective would indicate a potential upside of 28.76% from the company’s previous close.

SVRA has been the topic of several other research reports. Piper Sandler increased their price objective on shares of Savara from $7.00 to $16.00 and gave the stock an “overweight” rating in a research note on Monday, March 4th. JMP Securities reiterated a “market outperform” rating and set a $8.00 price target on shares of Savara in a research report on Monday, May 6th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $8.20.

Get Our Latest Report on Savara

Savara Price Performance

Shares of NASDAQ SVRA opened at $4.66 on Monday. The company has a current ratio of 14.90, a quick ratio of 14.90 and a debt-to-equity ratio of 0.22. The company has a market capitalization of $643.97 million, a price-to-earnings ratio of -12.59 and a beta of 0.73. Savara has a twelve month low of $1.87 and a twelve month high of $5.70. The business has a 50 day simple moving average of $4.88 and a 200-day simple moving average of $4.54.

Savara (NASDAQ:SVRAGet Free Report) last released its earnings results on Thursday, March 7th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.02. As a group, equities research analysts expect that Savara will post -0.38 earnings per share for the current year.

Institutional Investors Weigh In On Savara

Several large investors have recently made changes to their positions in SVRA. Vanguard Group Inc. grew its holdings in Savara by 2.5% in the 1st quarter. Vanguard Group Inc. now owns 6,063,620 shares of the company’s stock worth $30,197,000 after buying an additional 148,673 shares in the last quarter. ProShare Advisors LLC boosted its position in Savara by 9.0% during the 1st quarter. ProShare Advisors LLC now owns 25,715 shares of the company’s stock worth $128,000 after acquiring an additional 2,114 shares during the period. Susquehanna Fundamental Investments LLC acquired a new position in Savara during the 1st quarter worth $394,000. Swiss National Bank bought a new position in shares of Savara in the first quarter worth $732,000. Finally, Jennison Associates LLC increased its holdings in shares of Savara by 0.3% during the first quarter. Jennison Associates LLC now owns 8,841,971 shares of the company’s stock valued at $44,033,000 after purchasing an additional 26,613 shares during the period. Institutional investors and hedge funds own 87.93% of the company’s stock.

About Savara

(Get Free Report)

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

Featured Stories

Analyst Recommendations for Savara (NASDAQ:SVRA)

Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with's FREE daily email newsletter.